Raised in US dollars
*Includes $27,840 raised off platform.

We are extremely proud and honored to be an official Partner of John Hancock in the Marathon Non-Profit Program

What is ALS

  • Amyotrophic Lateral Sclerosis (ALS), is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. It begins with muscle weakness - sometimes in the arms or legs first, while sometimes it appears first with slurred speech or difficulty with swallowing.
  • Every 90 minutes, someone is diagnosed with the disease and someone passes away from it.
  • ALS can affect anyone worldwide regardless of racial, ethnic, or socioeconomic status. In general, symptoms commonly develop between the ages of 40 and 70, with the average being 55 years of age at diagnosis.
  • Most (about 90 percent) of ALS cases occur without family history, which is known as sporadic ALS. The remaining 10 percent of ALS cases are inherited through a mutated gene, which is known as familial ALS.
  • Currently, there is no cure for ALS but there are many promising clinical trials underway which require significant funding to advance.

ALS ONE is a partnership of world-leading ALS researchers, doctors, and care practitioners focused on finding treatments for ALS and novel approaches to improve care for individuals currently living with the disease. The unprecedented linking of minds and resources from Massachusetts General Hospital (MGH), University of Massachusetts Medical School (UMMS), ALS Therapy Development Institute (ALS TDI), and Compassionate Care ALS (CCALS), is unique for its leadership in efficiency, dedication to innovative research, and commitment to increasing access to care and treatment.ONE TEAM: Dr. Merit Cudkowicz, MD, MSc, Chief of Neurology, Massachusetts General Hospital (MGH); Dr. Robert Brown Jr., MD, DPhil, Chief of Neurology, UMass Medical School & Center; Dr. James Berry, MD, Co-Director of the MGH Neuromuscular Division and of the MGH ALS Unit, and he is an Associate Medical Director of the MGH Neurological Clinical Research Institute (NCRI); Dr. Fernando Vieira, MD., Chief Science Officer & CEO, ALS Therapy Development Institute; and Ron Hoffman, Founder and Director Compassionate Care ALS (CCALS).ONE GOAL: Identify a breakthrough treatment and ultimate cure while improving the care now for those battling ALS.

Please take a moment to be inspired by this video: 

If you would prefer to mail a check in support of one of our runners, please make out to ALS ONE and send to:

ALS ONE, 8 Industrial Way Whitman, MA 02382
Please include the runner's name in the memo portion of the check.

Visit us at: | By phone: 781-523-3304 | By Email: or

ALS ONE is a registered 501c3 non-profit organization.THANK YOU from the bottom of our green arrow on our logo, and the bottom of our hearts for supporting our team and our mission! 

YOU are truly making a difference!

8 Industrial Way
United States
Telephone: 7815233304
Registration #: EIN 47-4984263
Our Champions
Support our incredible champions. Swipe to see more.